ReviewMolecular interventions2011
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?
Review in Molecular interventions, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 126 citations in OpenAlex.
- Neurotoxicity of Synthetic Cannabinoid Receptor Agonist Cumyl-PINACA: An In Vitro Study on Rat Cortical Neurons and Astrocytes.Pharmaceuticals (Basel, Switzerland) · 2026Article
- An Outbreak of Synthetic Cannabinoid-Adulterated Tianeptine Products in New Jersey - Case Series.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2025Article
- Entropy drives the ligand recognition in G-protein-coupled receptor subtypes.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Abuse of Synthetic Cannabinoids and Cathinones in a Patient on Buprenorphine-Naloxone Treatment: A Case Report.Cureus · 2023Article
- Prenatal cannabinoid exposure: why expecting individuals should take a pregnancy pause from using cannabinoid products.Frontiers in pediatrics · 2023Review
- Phase I-metabolism studies of the synthetic cannabinoids PX-1 and PX-2 using three different in vitro models.Forensic toxicology · 2022Article
- Identification of Di/Tripeptide(s) With Osteoblasts Proliferation Stimulation Abilities of Yak Bone Collagen byFrontiers in nutrition · 2022Article
- Wonder or evil?: Multifaceted health hazards and health benefits ofSaudi journal of biological sciences · 2021Review
- Endogenous cannabinoids are required for MC4R-mediated control of energy homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Pharmacological and Toxicological Effects of Phytocannabinoids and Recreational Synthetic Cannabinoids: Increasing Risk of Public Health.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review.International journal of emergency medicine · 2021Review
- Article
- Article
- Regional trends in suspected synthetic cannabinoid exposure from January 2016 to September 2019 in the United States.Drug and alcohol dependence · 2020Article
- Assessing the acute effects of prenatal synthetic cannabinoid exposure on murine fetal brain vasculature using optical coherence tomography.Journal of biophotonics · 2019Article
- The Effects of Cannabinoids on Executive Functions: Evidence from Cannabis and Synthetic Cannabinoids-A Systematic Review.Brain sciences · 2018Review
- A synthetic cannabinoid JWH-210 reduces lymphoid organ weights and T-cell activator levels in mice via CBNaunyn-Schmiedeberg's archives of pharmacology · 2017Article
- Synthetic Cannabinoid-Induced Immunosuppression Augments Cerebellar Dysfunction in Tetanus-Toxin Treated Mice.Biomolecules & therapeutics · 2017Article
- Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.Current topics in behavioral neurosciences · 2017Review
- Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.World journal of clinical pediatrics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The principal psychoactive component of marijuana, Δ(9)-tetrahydrocannabinol (THC), activates CB1 cannabinoid receptors (CB1Rs). Unfortunately, pharmacological research into the design of effective THC analogs has been hampered by psychiatric side effects. THC-based drug design of a less academic nature, however, has led to the marketing of "synthetic marijuana," labeled as K2 or "Spice," among other terms, which elicits psychotropic actions via CB1R activation. Because of structural dissimilarity to THC, the active ingredients of K2/Spice preparations are widely unregulated. The K2/Spice "phenomenon" provides a context for considering whether marijuana-based drugs will truly provide innovative therapeutics or merely perpetuate drug abuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.